These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16397029)

  • 1. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
    Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN
    Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
    Stephan C; Xu C; Brown DA; Breit SN; Michael A; Nakamura T; Diamandis EP; Meyer H; Cammann H; Jung K
    Prostate; 2006 May; 66(6):651-9. PubMed ID: 16388506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
    Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro PSA : a "pro cancer" form of PSA?
    Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
    Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z; Jieming L; Su L; Wenlu S
    J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
    Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
    PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New circulating biomarkers for prostate cancer.
    Bensalah K; Lotan Y; Karam JA; Shariat SF
    Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.